These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38278145)

  • 1. Meta-Analysis of the Efficacy and Safety Evaluation of Vandetanib in the Treatment of Medullary Thyroid Cancer.
    Xian TC; Yang MY; Zhang XL; Wang J; Luo Y
    Horm Metab Res; 2024 Sep; 56(9):649-653. PubMed ID: 38278145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
    Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S
    Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer.
    Hu MI; Elisei R; Dedecjus M; Popovtzer A; Druce M; Kapiteijn E; Pacini F; Locati L; Krajewska J; Weiss R; Gagel RF
    Endocr Relat Cancer; 2019 Feb; 26(2):241-250. PubMed ID: 30557850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.
    Uchino K; Komoda M; Tomomatsu J; Okamoto T; Horiuchi K; Tsuji A; Ito Y; Todo T; Rito K; Takahashi S
    Endocr Pract; 2017 Feb; 23(2):149-156. PubMed ID: 27819766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and safety of vandetanib on advanced medullary thyroid carcinoma: single center result from a phase Ⅲ study].
    Wang SX; Zhang XW; Wang XX; An CM; Zhang YB; Liu W; Zhao YF; He XH; Li ZJ; Niu LJ; Tang PZ
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jun; 54(6):439-444. PubMed ID: 31262109
    [No Abstract]   [Full Text] [Related]  

  • 6. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
    Fallahi P; Ferrari SM; Baldini E; Biricotti M; Ulisse S; Materazzi G; Miccoli P; Antonelli A
    Expert Rev Anticancer Ther; 2016 Nov; 16(11):1109-1118. PubMed ID: 27650489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
    Brandenburg T; Tiedje V; Muchalla P; Theurer S; Weber F; Schmid KW; Dralle H; Führer D
    Front Endocrinol (Lausanne); 2021; 12():718418. PubMed ID: 34659114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vandetanib for the treatment of medullary thyroid cancer.
    Chau NG; Haddad RI
    Clin Cancer Res; 2013 Feb; 19(3):524-9. PubMed ID: 23231950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
    Chougnet CN; Borget I; Leboulleux S; de la Fouchardiere C; Bonichon F; Criniere L; Niccoli P; Bardet S; Schneegans O; Zanetta S; Schvartz C; Drui D; Chauffert B; Rohmer V; Schlumberger M
    Thyroid; 2015 Apr; 25(4):386-91. PubMed ID: 25627619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF; Adam P; Frank-Raue K; Raue F; Berg E; Hoster E; Allelein S; Schott M; Kroiss M; Spitzweg C
    Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
    [No Abstract]   [Full Text] [Related]  

  • 11. Vandetanib for the treatment of medullary thyroid carcinoma.
    Cooper MR; Yi SY; Alghamdi W; Shaheen DJ; Steinberg M
    Ann Pharmacother; 2014 Mar; 48(3):387-94. PubMed ID: 24259657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
    Wells SA; Robinson BG; Gagel RF; Dralle H; Fagin JA; Santoro M; Baudin E; Elisei R; Jarzab B; Vasselli JR; Read J; Langmuir P; Ryan AJ; Schlumberger MJ
    J Clin Oncol; 2012 Jan; 30(2):134-41. PubMed ID: 22025146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.
    Ton GN; Banaszynski ME; Kolesar JM
    Am J Health Syst Pharm; 2013 May; 70(10):849-55. PubMed ID: 23640345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.
    Kim M; Yoon JH; Ahn J; Jeon MJ; Kim HK; Lim DJ; Kang HC; Kim IJ; Shong YK; Kim TY; Kim BH
    Endocrinol Metab (Seoul); 2020 Sep; 35(3):587-594. PubMed ID: 32981301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
    Wells SA; Gosnell JE; Gagel RF; Moley J; Pfister D; Sosa JA; Skinner M; Krebs A; Vasselli J; Schlumberger M
    J Clin Oncol; 2010 Feb; 28(5):767-72. PubMed ID: 20065189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vandetanib (Caprelsa) for medullary thyroid cancer.
    Med Lett Drugs Ther; 2012 Jan; 54(1381):3-4. PubMed ID: 22233588
    [No Abstract]   [Full Text] [Related]  

  • 17. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
    Fox E; Widemann BC; Chuk MK; Marcus L; Aikin A; Whitcomb PO; Merino MJ; Lodish M; Dombi E; Steinberg SM; Wells SA; Balis FM
    Clin Cancer Res; 2013 Aug; 19(15):4239-48. PubMed ID: 23766359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety of vandetanib for the treatment of thyroid cancer.
    Tsang VH; Robinson BG; Learoyd DL
    Expert Opin Drug Saf; 2016 Aug; 15(8):1107-13. PubMed ID: 27301016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.
    Rosen AC; Wu S; Damse A; Sherman E; Lacouture ME
    J Clin Endocrinol Metab; 2012 Apr; 97(4):1125-33. PubMed ID: 22378813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.
    Del Rivero J; Edgerly M; Ward J; Madan RA; Balasubramaniam S; Fojo T; Gramza AW
    Oncologist; 2019 Jan; 24(1):16-e14. PubMed ID: 30297385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.